Sectors & IndustriesHealthcareDrug Manufacturers - General

Best General Drug Manufacturer Stocks to Buy Now (2023)

Top general drug manufacturer stocks in 2023 ranked by overall Zen Score. See the best general drug manufacturer stocks to buy now, according to analyst forecasts for the drug manufacturers - general industry.

According to Zen Score, the 3 best general drug manufacturer stocks to buy right now are:

Bristol Myers Squibb Co (NYSE:BMY) is the top general drug manufacturer stock with a Zen Score of 60, which is 17 points higher than the general drug manufacturer industry average of 43. It passed 22 out of 38 due diligence checks and has strong fundamentals. Bristol Myers Squibb Co has seen its stock lose -37.02% over the past year, underperforming other general drug manufacturer stocks by -39 percentage points.

Bristol Myers Squibb Co has an average 1 year price target of $64.81, an upside of 28.83% from Bristol Myers Squibb Co's current stock price of $50.31.

Bristol Myers Squibb Co stock has a consensus Buy recommendation according to Wall Street analysts. Of the 16 analysts covering Bristol Myers Squibb Co, 31.25% have issued a Strong Buy rating, 0% have issued a Buy, 62.5% have issued a hold, while 0% have issued a Sell rating, and 6.25% have issued a Strong Sell.

Johnson & Johnson (NYSE:JNJ) is the second best general drug manufacturer stock with a Zen Score of 60, which is 17 points higher than the general drug manufacturer industry average of 43. It passed 22 out of 38 due diligence checks and has strong fundamentals. Johnson & Johnson has seen its stock lose -12.86% over the past year, underperforming other general drug manufacturer stocks by -14 percentage points.

Johnson & Johnson has an average 1 year price target of $178.82, an upside of 15.8% from Johnson & Johnson's current stock price of $154.42.

Johnson & Johnson stock has a consensus Buy recommendation according to Wall Street analysts. Of the 11 analysts covering Johnson & Johnson, 27.27% have issued a Strong Buy rating, 18.18% have issued a Buy, 54.55% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Gilead Sciences (NASDAQ:GILD) is the third best general drug manufacturer stock with a Zen Score of 56, which is 13 points higher than the general drug manufacturer industry average of 43. It passed 20 out of 38 due diligence checks and has strong fundamentals. Gilead Sciences has seen its stock lose -11.68% over the past year, underperforming other general drug manufacturer stocks by -13 percentage points.

Gilead Sciences has an average 1 year price target of $84.11, an upside of 6.44% from Gilead Sciences's current stock price of $79.02.

Gilead Sciences stock has a consensus Buy recommendation according to Wall Street analysts. Of the 9 analysts covering Gilead Sciences, 33.33% have issued a Strong Buy rating, 0% have issued a Buy, 55.56% have issued a hold, while 11.11% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 13 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

Pfizer (NYSE:PFE) has an annual dividend yield of 5.7%, which is 2 percentage points higher than the general drug manufacturer industry average of 3.4%. Pfizer's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Pfizer's dividend has shown consistent growth over the last 10 years.

Pfizer's dividend payout ratio of 66.5% indicates that its high dividend yield is sustainable for the long-term.

Bristol Myers Squibb Co (NYSE:BMY) has an annual dividend yield of 4.53%, which is 1 percentage points higher than the general drug manufacturer industry average of 3.4%. Bristol Myers Squibb Co's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Bristol Myers Squibb Co's dividend has shown consistent growth over the last 10 years.

Bristol Myers Squibb Co's dividend payout ratio of 57.4% indicates that its dividend yield is sustainable for the long-term.

Sanofi (NASDAQ:SNY) has an annual dividend yield of 4.11%, which is 1 percentage points higher than the general drug manufacturer industry average of 3.4%. Sanofi's dividend payout is not stable, having dropped more than 10% two times in the last 10 years. Sanofi's dividend has not shown consistent growth over the last 10 years.

Sanofi's dividend payout ratio of 49.2% indicates that its dividend yield is sustainable for the long-term.

General drug manufacturer stocks were up 0.49% in the last day, and up 0.76% over the last week.

We couldn't find a catalyst for why general drug manufacturer stocks are up.

Based on WallStreetZen's Valuation Score, the 3 most undervalued general drug manufacturer stocks right now are:

Gsk (NYSE:GSK) is the most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Gsk has a valuation score of 71, which is 24 points higher than the general drug manufacturer industry average of 47. It passed 5 out of 7 valuation due diligence checks.

Gsk's stock has dropped -1.8% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -3 percentage points.

Astrazeneca (NASDAQ:AZN) is the second most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Astrazeneca has a valuation score of 71, which is 24 points higher than the general drug manufacturer industry average of 47. It passed 5 out of 7 valuation due diligence checks.

Astrazeneca's stock has dropped -8.56% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -10 percentage points.

Bristol Myers Squibb Co (NYSE:BMY) is the third most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Bristol Myers Squibb Co has a valuation score of 71, which is 24 points higher than the general drug manufacturer industry average of 47. It passed 5 out of 7 valuation due diligence checks.

Bristol Myers Squibb Co's stock has dropped -37.02% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -39 percentage points.